Compare Quest Diagnostics Inc (DGX) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MGM Resorts International — how do they compare? Quest Diagnostics Inc trades at $231.03 (market cap $25.48B), while MGM Resorts International trades at $29.53 (market cap $7.55B). The key difference: Quest Diagnostics Inc is far larger — about 3.4× MGM Resorts International's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and MGM Resorts International for 91 Days on average.
| DGX | MGM | |
|---|---|---|
Market Cap | $25.48B | $7.55B |
Volume | 941,866 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $50.69 |
52-Week Low | $173.49 | $30.00 |
Typical Hold Time | 56 Days | 91 Days |
Enterprise Value | $31.23B | $34.85B |
Dividend Yield | 1.49% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
MGM Resorts International (MGM) trades at $29.77, down 0.77% for the day amid a bearish technical signal and recent deal uncertainty. The stock has faced pressure after Barry Diller's People Inc. withdrew its $48.30 per share acquisition proposal in September 2026, contributing to a 17% decline year-to-date. Fundamentally, revenue grew to $17.54 billion in 2025, but net income margin compressed to 2.4%, while valuation metrics like a P/E of 18.19 and P/S of 0.45 suggest moderate pricing relative to sales. Analyst consensus remains bullish with a $48.75 price target, but technical indicators show selling pressure with key support at $29.
The outlook for MGM hinges on earnings execution and strategic moves, with Q3 2026 results due October 28 offering a near-term catalyst. Risks include volatile cash flows, high debt levels, and integration challenges from potential M&A. The stock's current discount to analyst targets presents opportunity if operational improvements materialize, but investors face headwinds from competitive pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
